Skip to main content
Top
Published in: Journal of Gastroenterology 9/2016

01-09-2016 | Original Article—Liver, Pancreas, and Biliary Tract

Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors

Authors: Keiichi Akahoshi, Shinji Tanaka, Kaoru Mogushi, Shu Shimada, Satoshi Matsumura, Yoshimitsu Akiyama, Arihiro Aihara, Yusuke Mitsunori, Daisuke Ban, Takanori Ochiai, Atsushi Kudo, Shigeki Arii, Minoru Tanabe

Published in: Journal of Gastroenterology | Issue 9/2016

Login to get access

Abstract

Background

The incidence of hepatocellular carcinoma (HCC) associated with metabolic risk factors, such as diabetes and obesity, has been increasing. However, the underlying mechanism that links these diseases remains unclear.

Methods

We performed genome-wide expression analysis of human liver tissues of non-viral HCC patients with or without metabolic risk factors. The upregulated genes that associated with diabetes and obesity were investigated by in vitro and in vivo experiments, and immunohistochemistry of human liver tissues was performed.

Results

Among the upregulated genes, connective tissue growth factor (CTGF) expression was induced to a greater extent by combined glucose and insulin administration to human hepatoma cells. Genome-wide expression analysis revealed upregulation of a chemokine network in CTGF-overexpressing hepatoma cells, which displayed an increased ability to induce in vitro activation of macrophages, and in vivo infiltration of liver macrophages. Immunohistochemistry of human liver tissues validated the correlations between CTGF expression and diabetes or obesity as well as activation of liver macrophages in patients with non-viral HCC. Recurrence-free survival was significantly poorer in the CTGF-positive patients compared with the CTGF-negative patients (p = 0.002). Multivariate analysis determined that CTGF expression (HR 2.361; 95 % CI 1.195–4.665; p = 0.013) and vascular invasion (HR 2.367; 95 % CI 1.270–4.410; p = 0.007) were independent prognostic factors for recurrence of non-viral HCC.

Conclusions

Our data suggest that CTGF could be involved in oncogenic pathways promoting non-viral HCC associated with metabolic risk factors via induction of liver inflammation and is expected to be a novel HCC risk biomarker and potential therapeutic target.
Appendix
Available only for authorised users
Literature
1.
go back to reference El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.CrossRefPubMed El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.CrossRefPubMed
2.
go back to reference Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90 (Erratum in: CA Cancer J Clin 2011;61:134).CrossRefPubMed Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90 (Erratum in: CA Cancer J Clin 2011;61:134).CrossRefPubMed
3.
go back to reference Davis GL, Dempster J, Meler JD, et al. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266–80. Davis GL, Dempster J, Meler JD, et al. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266–80.
4.
go back to reference Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110–7.CrossRefPubMed Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110–7.CrossRefPubMed
5.
go back to reference Caldwell SH, Crespo DM, Kang HS, et al. Obesity and hepatocellular carcinoma. Gastroenterology. 2004;127:S97–103.CrossRefPubMed Caldwell SH, Crespo DM, Kang HS, et al. Obesity and hepatocellular carcinoma. Gastroenterology. 2004;127:S97–103.CrossRefPubMed
7.
go back to reference Weng CJ, Hsieh YH, Tsai CM, et al. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1808–15.CrossRefPubMed Weng CJ, Hsieh YH, Tsai CM, et al. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1808–15.CrossRefPubMed
8.
go back to reference Karagozian R, Derdák Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism. 2014;63:607–17.CrossRefPubMed Karagozian R, Derdák Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism. 2014;63:607–17.CrossRefPubMed
9.
go back to reference Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut. 2010;59:1303–7.CrossRefPubMed Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut. 2010;59:1303–7.CrossRefPubMed
10.
go back to reference Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121–4 (Erratum in: Science 2009;326:1346).CrossRefPubMed Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121–4 (Erratum in: Science 2009;326:1346).CrossRefPubMed
11.
go back to reference Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197–208.CrossRefPubMedPubMedCentral Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197–208.CrossRefPubMedPubMedCentral
12.
go back to reference Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005;115:1503–21.CrossRefPubMedPubMedCentral Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005;115:1503–21.CrossRefPubMedPubMedCentral
13.
go back to reference Tanaka S, Arii S, Yasen M, et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg. 2008;95:611–9.CrossRefPubMed Tanaka S, Arii S, Yasen M, et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg. 2008;95:611–9.CrossRefPubMed
14.
go back to reference Murakata A, Tanaka S, Mogushi K, et al. Gene expression signature of the gross morphology in hepatocellular carcinoma. Ann Surg. 2011;253:94–100.CrossRefPubMed Murakata A, Tanaka S, Mogushi K, et al. Gene expression signature of the gross morphology in hepatocellular carcinoma. Ann Surg. 2011;253:94–100.CrossRefPubMed
15.
go back to reference Furuta K, Sato S, Yamauchi T, et al. Changes in intrahepatic gene expression profiles from chronic hepatitis to hepatocellular carcinoma in patients with hepatitis C virus infection. Hepatol Res. 2008;38:673–82.CrossRefPubMed Furuta K, Sato S, Yamauchi T, et al. Changes in intrahepatic gene expression profiles from chronic hepatitis to hepatocellular carcinoma in patients with hepatitis C virus infection. Hepatol Res. 2008;38:673–82.CrossRefPubMed
16.
17.
go back to reference Tanaka S. CCN4 and CCN6 variants in Wnt-inducible signaling pathway. In: Perbal P, Takigawa M, editors. CCN proteins: a new family of cell growth and differentiation regulators. London: Imperial College Press; 2005. p. 293–304.CrossRef Tanaka S. CCN4 and CCN6 variants in Wnt-inducible signaling pathway. In: Perbal P, Takigawa M, editors. CCN proteins: a new family of cell growth and differentiation regulators. London: Imperial College Press; 2005. p. 293–304.CrossRef
18.
go back to reference Tanaka S, Pero SC, Taguchi K, et al. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. J Natl Cancer Inst. 2006;98:491–8.CrossRefPubMed Tanaka S, Pero SC, Taguchi K, et al. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. J Natl Cancer Inst. 2006;98:491–8.CrossRefPubMed
19.
go back to reference Ogawa K, Tanaka S, Matsumura S, et al. EpCAM-targeted therapy for human hepatocellular carcinoma. Ann Surg Oncol. 2014;21:1314–22.CrossRefPubMed Ogawa K, Tanaka S, Matsumura S, et al. EpCAM-targeted therapy for human hepatocellular carcinoma. Ann Surg Oncol. 2014;21:1314–22.CrossRefPubMed
20.
go back to reference Aihara A, Tanaka S, Yasen M, et al. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol. 2010;52:63–71.CrossRefPubMed Aihara A, Tanaka S, Yasen M, et al. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol. 2010;52:63–71.CrossRefPubMed
21.
go back to reference Coulouarn C, Lefebvre G, Daveau R, et al. Genome-wide response of the human Hep3B hepatoma cell to proinflammatory cytokines, from transcription to translation. Hepatology. 2005;42:946–55.CrossRefPubMed Coulouarn C, Lefebvre G, Daveau R, et al. Genome-wide response of the human Hep3B hepatoma cell to proinflammatory cytokines, from transcription to translation. Hepatology. 2005;42:946–55.CrossRefPubMed
22.
go back to reference Slany A, Haudek VJ, Zwickl H, et al. Cell characterization by proteome profiling applied to primary hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B. J Proteome Res. 2010;9:6–21.CrossRefPubMed Slany A, Haudek VJ, Zwickl H, et al. Cell characterization by proteome profiling applied to primary hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B. J Proteome Res. 2010;9:6–21.CrossRefPubMed
23.
go back to reference Tanaka S, Wands JR. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res. 1996;56:3391–4.PubMed Tanaka S, Wands JR. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res. 1996;56:3391–4.PubMed
24.
go back to reference Byun JK, Choi YK, Kang YN, et al. Retinoic acid-related orphan receptor alpha reprograms glucose metabolism in glutamine-deficient hepatoma cells. Hepatology. 2015;61:953–64.CrossRefPubMed Byun JK, Choi YK, Kang YN, et al. Retinoic acid-related orphan receptor alpha reprograms glucose metabolism in glutamine-deficient hepatoma cells. Hepatology. 2015;61:953–64.CrossRefPubMed
25.
go back to reference Tanaka S, Mogushi K, Yasen M, et al. Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study. Hepatology. 2011;54:1273–81.CrossRefPubMed Tanaka S, Mogushi K, Yasen M, et al. Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study. Hepatology. 2011;54:1273–81.CrossRefPubMed
26.
27.
go back to reference Sánchez-López E, Rayego S, Rodrigues-Díez R, et al. CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappaB. J Am Soc Nephrol. 2009;20:1513–26.CrossRefPubMedPubMedCentral Sánchez-López E, Rayego S, Rodrigues-Díez R, et al. CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappaB. J Am Soc Nephrol. 2009;20:1513–26.CrossRefPubMedPubMedCentral
29.
go back to reference Murphy M, Godson C, Cannon S, et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem. 1999;274:5830–4.CrossRefPubMed Murphy M, Godson C, Cannon S, et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem. 1999;274:5830–4.CrossRefPubMed
30.
go back to reference Wahab NA, Schaefer L, Weston BS, et al. Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia. 2005;48:2650–60.CrossRefPubMed Wahab NA, Schaefer L, Weston BS, et al. Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia. 2005;48:2650–60.CrossRefPubMed
31.
go back to reference Kuiper EJ, van Zijderveld R, Roestenberg P, et al. Connective tissue growth factor is necessary for retinal capillary basal lamina thickening in diabetic mice. J Histochem Cytochem. 2008;56:785–92.CrossRefPubMedPubMedCentral Kuiper EJ, van Zijderveld R, Roestenberg P, et al. Connective tissue growth factor is necessary for retinal capillary basal lamina thickening in diabetic mice. J Histochem Cytochem. 2008;56:785–92.CrossRefPubMedPubMedCentral
32.
go back to reference Liu X, Luo F, Pan K, et al. High glucose upregulates connective tissue growth factor expression in human vascular smooth muscle cells. BMC Cell Biol. 2007;16(8):1.CrossRef Liu X, Luo F, Pan K, et al. High glucose upregulates connective tissue growth factor expression in human vascular smooth muscle cells. BMC Cell Biol. 2007;16(8):1.CrossRef
33.
go back to reference Liu SC, Hsu CJ, Fong YC, et al. CTGF induces monocyte chemoattractant protein-1 expression to enhance monocyte migration in human synovial fibroblasts. Biochim Biophys Acta. 2013;1833:1114–24.CrossRefPubMed Liu SC, Hsu CJ, Fong YC, et al. CTGF induces monocyte chemoattractant protein-1 expression to enhance monocyte migration in human synovial fibroblasts. Biochim Biophys Acta. 2013;1833:1114–24.CrossRefPubMed
34.
go back to reference Chujo S, Shirasaki F, Kondo-Miyazaki M, et al. Role of connective tissue growth factor and its interaction with basic fibroblast growth factor and macrophage chemoattractant protein-1 in skin fibrosis. J Cell Physiol. 2009;220:189–95.CrossRefPubMed Chujo S, Shirasaki F, Kondo-Miyazaki M, et al. Role of connective tissue growth factor and its interaction with basic fibroblast growth factor and macrophage chemoattractant protein-1 in skin fibrosis. J Cell Physiol. 2009;220:189–95.CrossRefPubMed
35.
go back to reference Charrier A, Chen R, Kemper S, et al. Regulation of pancreatic inflammation by connective tissue growth factor (CTGF/CCN2). Immunology. 2014;141:564–76.CrossRefPubMedPubMedCentral Charrier A, Chen R, Kemper S, et al. Regulation of pancreatic inflammation by connective tissue growth factor (CTGF/CCN2). Immunology. 2014;141:564–76.CrossRefPubMedPubMedCentral
36.
go back to reference Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738–44.CrossRefPubMed Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738–44.CrossRefPubMed
37.
go back to reference Lo L, McLennan SV, Williams PF, et al. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol. 2011;55:435–44.CrossRefPubMed Lo L, McLennan SV, Williams PF, et al. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol. 2011;55:435–44.CrossRefPubMed
38.
go back to reference Chen L, Charrier AL, Leask A, et al. Ethanol-stimulated differentiated functions of human or mouse hepatic stellate cells are mediated by connective tissue growth factor. J Hepatol. 2011;55:399–406.CrossRefPubMed Chen L, Charrier AL, Leask A, et al. Ethanol-stimulated differentiated functions of human or mouse hepatic stellate cells are mediated by connective tissue growth factor. J Hepatol. 2011;55:399–406.CrossRefPubMed
39.
go back to reference Llovet JM, Villanueva A, Lachenmayer A, et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408–24.CrossRefPubMed Llovet JM, Villanueva A, Lachenmayer A, et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408–24.CrossRefPubMed
40.
go back to reference Barashi N, Weiss ID, Wald O, et al. Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. Hepatology. 2013;58:1021–30.CrossRefPubMed Barashi N, Weiss ID, Wald O, et al. Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. Hepatology. 2013;58:1021–30.CrossRefPubMed
41.
go back to reference He G, Dhar D, Nakagawa H, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 2013;155:384–96.CrossRefPubMedPubMedCentral He G, Dhar D, Nakagawa H, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 2013;155:384–96.CrossRefPubMedPubMedCentral
42.
go back to reference Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499:97–101.CrossRefPubMed Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499:97–101.CrossRefPubMed
43.
go back to reference Perng DW, Wu YC, Tsai CC, et al. Bile acids induce CCN2 production through p38 MAP kinase activation in human bronchial epithelial cells: a factor contributing to airway fibrosis. Respirology. 2008;13:983–9.PubMed Perng DW, Wu YC, Tsai CC, et al. Bile acids induce CCN2 production through p38 MAP kinase activation in human bronchial epithelial cells: a factor contributing to airway fibrosis. Respirology. 2008;13:983–9.PubMed
44.
go back to reference Neesse A, Frese KK, Bapiro TE, et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci USA. 2013;110:12325–30.CrossRefPubMedPubMedCentral Neesse A, Frese KK, Bapiro TE, et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci USA. 2013;110:12325–30.CrossRefPubMedPubMedCentral
45.
go back to reference Adler SG, Schwartz S, Williams ME, et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol. 2010;5:1420–8.CrossRefPubMedPubMedCentral Adler SG, Schwartz S, Williams ME, et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol. 2010;5:1420–8.CrossRefPubMedPubMedCentral
Metadata
Title
Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors
Authors
Keiichi Akahoshi
Shinji Tanaka
Kaoru Mogushi
Shu Shimada
Satoshi Matsumura
Yoshimitsu Akiyama
Arihiro Aihara
Yusuke Mitsunori
Daisuke Ban
Takanori Ochiai
Atsushi Kudo
Shigeki Arii
Minoru Tanabe
Publication date
01-09-2016
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 9/2016
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-015-1159-8

Other articles of this Issue 9/2016

Journal of Gastroenterology 9/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine